Frank Mottola Sells 4,780 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) SVP Frank Mottola sold 4,780 shares of the firm’s stock in a transaction on Tuesday, March 14th. The stock was sold at an average price of $35.99, for a total value of $172,032.20. Following the completion of the sale, the senior vice president now directly owns 4,737 shares of the company’s stock, valued at $170,484.63. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Supernus Pharmaceuticals Trading Down 2.9 %

Shares of NASDAQ:SUPN opened at $34.93 on Friday. The business has a 50-day moving average price of $39.07 and a 200 day moving average price of $36.24. The company has a market capitalization of $1.90 billion, a price-to-earnings ratio of 33.91 and a beta of 1.01. Supernus Pharmaceuticals, Inc. has a 12-month low of $24.95 and a 12-month high of $42.09.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last announced its earnings results on Tuesday, February 28th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, missing analysts’ consensus estimates of $0.73 by ($0.30). Supernus Pharmaceuticals had a net margin of 9.10% and a return on equity of 7.12%. The firm had revenue of $167.33 million for the quarter, compared to analysts’ expectations of $180.38 million. During the same quarter last year, the business earned $0.04 earnings per share. The business’s revenue was up 5.2% compared to the same quarter last year. As a group, equities research analysts predict that Supernus Pharmaceuticals, Inc. will post 0.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. StockNews.com initiated coverage on Supernus Pharmaceuticals in a research note on Thursday. They issued a “buy” rating for the company. TheStreet raised Supernus Pharmaceuticals from a “c+” rating to a “b+” rating in a research report on Tuesday, February 28th. Finally, Piper Sandler raised their price objective on Supernus Pharmaceuticals from $40.00 to $47.00 and gave the stock an “overweight” rating in a research report on Monday, January 23rd.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Macquarie Group Ltd. boosted its holdings in Supernus Pharmaceuticals by 2.1% during the 4th quarter. Macquarie Group Ltd. now owns 2,420,534 shares of the specialty pharmaceutical company’s stock valued at $86,340,000 after acquiring an additional 50,414 shares during the period. Point72 Middle East FZE purchased a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $57,000. State of Wyoming boosted its holdings in Supernus Pharmaceuticals by 68.5% during the 4th quarter. State of Wyoming now owns 6,321 shares of the specialty pharmaceutical company’s stock valued at $225,000 after acquiring an additional 2,569 shares during the period. Seaport Global Advisors LLC purchased a new position in Supernus Pharmaceuticals during the 4th quarter valued at about $286,000. Finally, Schonfeld Strategic Advisors LLC boosted its stake in shares of Supernus Pharmaceuticals by 292.3% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 65,905 shares of the specialty pharmaceutical company’s stock valued at $2,351,000 after buying an additional 49,105 shares during the period. 99.82% of the stock is currently owned by hedge funds and other institutional investors.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.